Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Clinical, Radiological and Electrophysiological Comparison of Immunomodulatory Therapies in Multiple Sclerosis.

Genç G, Demirkaya Ş, Bek S, Odabaşi Z.

Noro Psikiyatr Ars. 2017 Jun;54(2):116-124. doi: 10.5152/npa.2016.12621. Epub 2016 Mar 1.

2.

Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE.

Benešová Y, Tvaroh A.

Ther Adv Neurol Disord. 2017 Jan;10(1):18-32. doi: 10.1177/1756285616671882. Epub 2016 Oct 21.

3.

Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.

Link J, Ramanujam R, Auer M, Ryner M, Hässler S, Bachelet D, Mbogning C, Warnke C, Buck D, Hyldgaard Jensen PE, Sievers C, Ingenhoven K, Fissolo N, Lindberg R, Grummel V, Donnellan N, Comabella M, Montalban X, Kieseier B, Soelberg Sørensen P, Hartung HP, Derfuss T, Lawton A, Sikkema D, Pallardy M, Hemmer B, Deisenhammer F, Broët P, Dönnes P, Davidson J, Fogdell-Hahn A; ABIRISK Consortium.

PLoS One. 2017 Feb 7;12(2):e0170395. doi: 10.1371/journal.pone.0170395. eCollection 2017.

4.

Autoinjector preference in multiple sclerosis and the role of nurses in treatment decisions: results from an international survey in Europe and the USA.

Verdun di Cantogno E, Tomlinson M, Manuel L, Thakur K.

Pragmat Obs Res. 2014 Dec 12;5:53-64. eCollection 2014.

5.
6.

Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations.

Prosperini L, Pontecorvo S.

Ther Clin Risk Manag. 2016 Mar 2;12:339-50. doi: 10.2147/TCRM.S85099. eCollection 2016. Review.

7.

Disease-modifying treatments for multiple sclerosis - a review of approved medications.

Torkildsen Ø, Myhr KM, Bø L.

Eur J Neurol. 2016 Jan;23 Suppl 1:18-27. doi: 10.1111/ene.12883. Review.

8.

Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis.

Farber RS, Sand IK.

Ther Adv Neurol Disord. 2015 Sep;8(5):212-32. doi: 10.1177/1756285615598910. Review.

9.

Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis.

Subei AM, Ontaneda D.

CNS Drugs. 2015 Sep;29(9):759-71. doi: 10.1007/s40263-015-0277-4. Review.

10.

Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?

Gajofatto A, Benedetti MD.

World J Clin Cases. 2015 Jul 16;3(7):545-55. doi: 10.12998/wjcc.v3.i7.545. Review.

11.

Differential effects of IFN-β on IL-12, IL-23, and IL-10 expression in TLR-stimulated dendritic cells.

Yen JH, Kong W, Hooper KM, Emig F, Rahbari KM, Kuo PC, Scofield BA, Ganea D.

J Leukoc Biol. 2015 Nov;98(5):689-702. doi: 10.1189/jlb.3HI0914-453R. Epub 2015 Jun 9.

12.

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis.

Cocco E, Marrosu MG.

Ther Clin Risk Manag. 2015 May 8;11:759-66. doi: 10.2147/TCRM.S69123. eCollection 2015. Review.

13.

A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.

Tolley K, Hutchinson M, You X, Wang P, Sperling B, Taneja A, Siddiqui MK, Kinter E.

PLoS One. 2015 Jun 3;10(6):e0127960. doi: 10.1371/journal.pone.0127960. eCollection 2015. Review.

14.

Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis.

Wiendl H, Meuth SG.

Drugs. 2015 Jun;75(9):947-77. doi: 10.1007/s40265-015-0411-0. Review.

15.

Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis.

Marziniak M, Meuth S.

Adv Ther. 2014 Sep;31(9):915-31. doi: 10.1007/s12325-014-0149-1. Epub 2014 Sep 3. Review.

16.

Cytokines as Biomarkers of Treatment Response to IFN β in Relapsing-Remitting Multiple Sclerosis.

Dimisianos N, Rodi M, Kalavrizioti D, Georgiou V, Papathanasopoulos P, Mouzaki A.

Mult Scler Int. 2014;2014:436764. doi: 10.1155/2014/436764. Epub 2014 Jul 22.

17.

Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.

Du Pasquier RA, Pinschewer DD, Merkler D.

CNS Drugs. 2014 Jun;28(6):535-58. doi: 10.1007/s40263-014-0160-8. Review.

18.

In vitro assessment of the biologic activity of interferon beta formulations used for the treatment of relapsing multiple sclerosis.

Scagnolari C, Selvaggi C, Di Biase E, Fraulo M, Dangond F, Antonelli G.

J Immunoassay Immunochem. 2014;35(3):288-99. doi: 10.1080/15321819.2013.848815.

19.
20.

Assessing treatment response to interferon-β: is there a role for MRI?

Dobson R, Rudick RA, Turner B, Schmierer K, Giovannoni G.

Neurology. 2014 Jan 21;82(3):248-54. doi: 10.1212/WNL.0000000000000036. Epub 2013 Dec 11. Review.

Supplemental Content

Support Center